Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776602 | 1.00 | FFAR1 (0.55) | FFAR1TSHRPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL10272652 | 0.88 | RAB9A (0.58) | FFAR1TSHRCYP4F2CYP4A11 | |
| SCHEMBL14747475 | 0.88 | FFAR1 (0.52) | FFAR1TSHRCYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL2776446 | 0.84 | SLC6A2 (0.56) | TSHRPOLBKMT2AGPR88SLC6A2 | |
| SCHEMBL15091893 | 0.84 | FFAR1 (0.52) | FFAR1FFAR4CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL31729334 | 0.84 | FFAR1 (0.52) | FFAR1FFAR4CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL2776444 | 0.84 | SLC6A2 (0.56) | TSHRPOLBKMT2AGPR88SLC6A2 | |
| SCHEMBL12577538 | 0.83 | FFAR1 (0.53) | FFAR1FFAR4CYP4F2CYP4A11 | |
| SCHEMBL2961573 | 0.82 | SLC9A1 (0.49) | FFAR1SMN1; SMN2FFAR4CYP4F2CYP4A11 | |
| SCHEMBL18596476 | 0.81 | RAB9A (0.57) | FFAR1KMT2ASMN1; SMN2GPR88L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | FFAR1 3115/4885TSHR 423/4885POLB 773/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | FFAR1 3414/4885TSHR 1034/4885POLB 664/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | FFAR1 3414/4885TSHR 1034/4885POLB 664/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | FFAR1 3779/4885TSHR 2282/4885POLB 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.